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At the end of March/beginning of April 2009, a new 
type A influenza virus, subtype H1N1 (A/H1N1v), ap-
peared on the world epidemiological scene. This sub-
type emerged from the re-assortment of two viruses that 
had long been present in swine in Americas and Eurasia 
respectively [1]. The first human cases of illness were 
reported in Mexico and the United States, and within a 
few weeks the virus had spread worldwide with unprec-
edented speed through direct person-to-person trans-
mission. On account of this rapid evolution, attention 
regarding preparation and the response to the influenza 
pandemic was raised by the World Health Organization 
(WHO) to the maximum level of alert, level 6 (on 11th 
June 2009), corresponding to an increased and prolonged 
transmission of the virus in the populations of numerous 
countries in the world [2].
With regard to the susceptibility of the world population 
to the new virus, studies carried out by the Centers for 
Disease Control and Prevention (CDC) on serum sam-
ples gathered before the beginning of the pandemic re-
vealed that a high percentage of subjects aged > 60 years 
possessed antibodies against the new virus; a consider-
able proportion of subjects with antibodies against A/
H1N1v was also detected in the 18-60-year age-group, 
while cross-reactive antibodies were not found in chil-
dren or adolescents (< 18 years) [3]. These findings sug-
gest that some degree of pre-existing immunity towards 
the new virus was present in adults and, especially, the 
elderly. The most probable explanation for this is that 
these two age-groups had already been exposed to the 
virus either through infection or vaccination with an A/
H1N1virus that was partially related, genetically and an-
tigenically, to the new A/H1N1v.
This background situation influenced the course of the 
pandemic. Indeed, the new virus spread easily among chil-
dren and adolescents, causing an important pre-seasonal 
(October-November) epidemic peak both in Italy and in 
the temperate zones of the northern hemisphere, while the 
incidence in adults and elderly subjects was low [4].
The rapidity of the spread of the virus and the risks of se-
rious public health consequences prompted activation of 
the pandemic plan [5] which had previously been drawn 
up following the alarm caused by the H5N1 virus (avian 
flu). In Italy, various monitoring systems, some already 
operating and some newly implemented, enabled the 
course of the pandemic and its consequences to be con-
trolled. Epidemiological surveillance, based on a net-
work of sentinel physicians recruited by the various Ital-
ian Regions, revealed that the epidemic reached its peak 
in the 46th week, with an incidence of about 13 cases per 
1000 residents assisted by the National Health Service: a 
higher value than that reached in the four previous influ-
enza seasons, though lower than in 2004-2005 (Fig. 1). 
Moreover, the curve of the epidemic displayed a narrow-
er base than the previous epidemics, owing to the rapid 
decline in incidence. From the 43rd week of 2009 to the 
first week of May 2010, it was estimated that 5,582.000 
new cases of influenza syndrome occurred [6].
In comparison with previous years, the 2009-10 season 
displayed two substantial differences due to the unfore-
seen circulation of the new virus. Indeed, a sharp rise in 
the epidemic curve occurred several weeks earlier than 
in the typical influenza season, followed by an equally 
rapid decline a few weeks later. Moreover, the peak 
of morbidity chiefly involved the 5-14-year age-group 
(Fig. 2), with the virus spreading rapidly among school-
children; by contrast, intra-family transmission proved 
to be lower than expected.
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Fig. 1. Incidence of influenza epidemics from the 2004-05 season 
to the 2009-10 season. 
Source: ministry of health, Influnet.
Fig. 2. Incidence of influenza by age-class in the seasons 2008-09 
and 2009-10.
Source: ministry of health, Influnet.
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Another representative finding was provided by the vi-
rological surveillance. Analyzing the data of the Inter-
University Centre for Research on Influenza and Viral 
Infections, based on a network of laboratories which 
carry out surveillance through samples collected both by 
sentinel physicians and by hospitals, it showed that the 
A/H1N1v has clearly dominated the virological scene; 
only a few type B strains were isolated from children in 
January-February 2010 (Fig. 3).
In addition, the number of accesses to emergency de-
partments for acute respiratory syndrome (principal 
diagnosis based at least on  one  of these ICD IXCM 
codes: 462, 466, 480, 487, 786, 793, 780) was monitored 
in several Italian Regions, as this is an indirect indica-
tor of the activity of influenza viruses. The number of 
admissions began to rise in the 41st week and peaked 
in the 44th week, when the epidemic alert threshold was 
exceeded in all age-groups except for persons over 65 
years old (Fig. 4) [7, 8]. The alert threshold has been 
estimated using  a statistical model of cyclical regres-
sion based on historical data sent to emergency room. 
Weekly data collected were compared with the baseline 
calculated by the model.
A special surveillance programme was also activated to 
monitor deaths linked to the new A/H1N1v. A total of 
259 deaths were recorded from the beginning of the epi-
demic. Of these, 41.7% were of women; the age-groups 
most affected were those of subjects from 15 to 44 years 
of age (32.4% of deaths) and from 45 to 64 years (34%). 
The most severely affected Regions were Campania, with 
52 deaths, followed by Puglia (36), Lazio (29), Piedmont 
(26), Sicily (24) and Calabria (16). Two Regions (Valle 
d’Aosta and Sardinia) did not register any deaths [5]. As 
pointed out by the WHO, virologically ascertained deaths 
Fig. 3. virological surveillance from the 1999-2000 season to the 2009-10 season. 
Source: Inter-University Centre for research on Influenza and viral Infections.
are to be distinguished from those calculated statistically 
each year as excess mortality [9, 10].
The initial data provided by national and international sur-
veillance programmes indicated the trend in A/H1N1v in-
fections and revealed a significant incidence of respirato-
ry complications, especially of pneumonia rapidly evolv-
ing to Acute Respiratory Distress Syndrome (ARDS), 
particularly in young adults. Accordingly, in November 
2009, the national network for the management of ARDS 
caused by pneumonia due to A/H1N1v and the possible 
use of ECMO (Extra Corporeal Membrane Oxygena-
tion) therapy was set up [11]. Although most A/H1N1v 
infections were clinically mild or moderate, in some cases 
major pulmonary complications arose. The high quality 
of clinical management of patients with severe complica-
tions in intensive care units undoubtedly saved many lives 
and avoided the need for prolonged hospitalisation.
Containment measures (diagnostic tests, voluntary isola-
tion, personal hygiene, anti-viral prophylaxis) proved ef-
fective from May to September 2009. Nevertheless, con-
sidering that the most efficacious means of containing a 
pandemic is vaccination, a specific vaccine was speedily 
produced, in accordance with the indications of the WHO 
and the regulations of the European Medicines Agency 
(EMA), and the preparation Focetria® (Novartis) became 
available in Italy in the second half of October 2009 [12]. 
A campaign of immunisation with the pandemic mono-
valent vaccine was then launched. Initially, this was 
aimed at Health Care Workers, workers in essential 
public services and those subjects aged < 65 years who 
were at risk of complications in the event of infection 
(Ministry of Health ordinances of 11th and 30th Septem-
ber 2009; Ministry of Health ordinance of 3rd December 
2009) [13-15]. 
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Unfortunately, however, as a result both of the fact that 
the vaccine became available when the epidemic had al-
ready started and of misinformation regarding the safety 
and efficacy of the vaccine with respect to a pathology 
that was regarded as mild, overall compliance with vac-
cination was low in comparison with the level predicted 
by the previously constructed models.
By contrast, in other European countries broader ap-
proaches were adopted; a large portion of the popula-
tion was vaccinated without distinction in terms of in-
dividual characteristics or age-group. In Italy, a total of 
871,277 first doses and 52,782 second doses were ad-
ministered [5]. The category which registered the highest 
rate of vaccine coverage (15%) was that of Health Care 
Workers, while among at-risk subjects aged between 6 
months and 65 years and among women in the second 
and third trimesters of pregnancy, coverage rates were 
12.7% and 12.1%, respectively. Babies born preterm re-
ceived 1595 doses (vaccine coverage 7.7%), while at-risk 
subjects aged > 65 years registered a coverage rate of 
1.9%. This low value can be ascribed to the fact that the 
vaccination of this group of subjects became possible on-
ly in December, when the curve of the epidemic was de-
clining and the pandemic risk was less acutely perceived. 
Fig. 4. emergency department accesses and hospitalisations for acute respiratory syndrome and weekly incidence of influenza-like syn-
dromes.
Source: higher Institute of health, flunews.
Tab. I. vaccine coverage by subject category. 
Category Doses 
administered
Population eligible
Vaccine coverage 
(%)
health Care Workers 160,659 1,069,264 15.03
Subjects aged from 6 months to 65 years with at least one 
risk condition
549,167 4,309,466
12.74
Women in the second or third trimester of pregnancy 23,016 189,915 12.12
minors living in communities or institutions (not included in 
the above categories) 
1,120 10,155 11.03
Subjects aged < 24 months born seriously preterm 1,595 20,657 7.72
Security forces and Civil protection staff
firefighters and Interior ministry staff
armed forces
essential public services
72,181 1,228,155
5.88
Children aged > 6 months attending nurseries (not included 
in the above categories)
4,618 89,394 5.17
Women who had given birth within the previous 6 months or 
the person caring for the baby 
8,170 237,594 3.44
Subjects aged > 65 years with at least one risk condition 13,562 710,862 1.91
periodic blood donors 6,329 742,349 0.85
healthy subjects aged from 6 months to 17 years 20,307 7,671,581 0.26
healthy subjects aged from 18 to 27 years 5,650 4,642,188 0.12
Subtotal 866,374 20,921,580 4.14
Subjects not included in the above categories 4,903
total 871,277
Source: higher Institute of health, flunews.
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Overall vaccine coverage proved to be 4.1% (Tab. I). On 
the whole, the damage caused by the first wave of the 
new influenza pandemic in the 2009-2010 season was 
reasonably contained even though the liaison between 
central and regional authorities was not always optimal 
and the level of preparation for the pandemic differed 
from one region to another. Nevertheless, influenza was 
again confirmed as a socially serious illness that can 
cause hospitalisation and death. Its unpredictable nature, 
which fascinates researchers, requires continuous and 
thorough surveillance on the part of healthcare authori-
ties. Moreover, surveillance should not be restricted to 
the human population, but extended to animal species, 
particularly swine and birds.
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